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Abstract: The	tretinoin	peel,	also	known	as	retinoic	acid	peel,	is	a	superficial	peeling	often	performed	in	dermatological	clinics	
in	Brazil.	The	first	study	on	this	was	published	in	2001,	by	Cuce	et al.,	as	a	treatment	option	for	melasma.	Since	then,	other	
studies	have	reported	its	applicability	with	reasonable	methodology,	although	without	a	consistent	scientific	background	and	
consensus.	Topical	tretinoin	is	used	for	the	treatment	of	various	dermatoses	such	as	acne,	melasma,	scars,	skin	aging	and	non-
melanoma	skin	cancer.	The	identification	of	retinoids	cellular	receptors	was	reported	in	1987,	but	a	direct	cause-effect	relation	
has	not	been	established.	This	article	reviews	studies	evaluating	the	use	of	topical	tretinoin	as	agent	for	superficial	chemical	
peel.	Most	of	them	have	shown	benefits	in	the	treatment	of	melasma	and	skin	aging.	A	better	quality	methodology	in	the	study	
design,	 considering	 indication	 and	 intervention	 is	 indispensable	 regarding	 concentration,	 vehicle	 and	 treatment	 regimen	
(interval	and	number	of	applications).	Additionally,	more	controlled	and	randomized	studies	comparing	the	treatment	with	
tretinoin	cream	versus	its	use	as	a	peeling	agent,	mainly	for	melasma	and	photoaging,	are	necessary.	
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TRETINOIN OR ALL-TRANS RETINOIC ACID 
The	 liposoluble	vitamin	A	 is	essential	 to	 the	human	body	
and only available in the diet. Its molecule is an alcohol and there-
fore	is	called	“retinol”.	It	is	absorbed	by	the	small	intestine,	stored	
in	the	liver	as	retinyl	esters	(palmitate	and	ethyl	propionate),	or	con-
verted	to	active	metabolites	such	as	tretinoin,	with	an	intermediate	
form called retinaldehyde. The conversion of retinol into retinyl es-
ters	and	retinaldehyde	 is	 reversible,	whereas	 the	retinaldehyde	 to	
retinoic acid is irreversible.
Tretinoin	or	all-trans	retinoic	acid	represents	50%	of	the	ac-
tive	cellular	form,	with	its	metabolites	(4-hydroxy-retinoic	acid)	and	
stereoisomers	 9-cis-retinoic	 acid	 (alitretinoin)	 and	 13-cis-retinoic	
acid	(isotretinoin)	making	up	the	difference.1
Thus,	in	topical	application,	retinol,	retinol	esters,	and	ret-
inaldehyde	have	to	be	converted	to	a	more	active	form	(tretinoin),	
whereas	isotretinoin,	alitretinoin,	adapalene,	tazarotene	and	seleti-
noid G are already applied in their active form. 
The discovery of the receptors for retinoic acid in 1987 was 
the	first	demonstration	of	a	retinoid-responsive	transcription	factor.2,3
Tretinoin activates three nuclear retinoic acid receptors 
(RAR-alpha,	RAR-beta	and	RAR-gamma).	The	retinoic	acid	recep-
tors	(RARs)	bind	to	regulatory	regions	in	DNA	called	retinoic	acid	
response	elements	(RAREs)	or	target	sequences,	and	activate	many	
gene	transcriptions.	Tretinoin	may	exert	its	clinical	effects,	at	least	in	
part,	through	activation	of	retinoid	receptors.4,5
The	binding	profile	of	tretinoin	differs	from	that	of	synthetic	
retinoids,	such	as	adapalene,	which	binds	preferentially	to	RAR-be-
ta	and	RAR-gamma,	and	tazarotene,	which	binds	to	all	3	RARs	but	
appears	 to	 lead	 to	an	effective	gene	expression	only	by	RAR-beta	
and	RAR-gamma.6
Topical tretinoin application before ultraviolet irradiation 
has been shown to prevent matrix metalloproteinase production 
and collagen degradation.7
Histologically,	 increased	collagen	types	I,	 III	and	VII	 (der-
mal-epidermal	anchoring	fibrils)	production	can	be	seen,	as	well	as	
reorganization	of	the	dermal	collagen	into	new	woven	bundles.8
Topical tretinoin has been shown to increase production of 
type	I	collagen	by	80%	in	photoaged	skin.9
It is thought that the increased collagen content indirectly 
stimulates	normalization	of	the	elastic	tissue	organization.10
Increased smoothness of skin or wrinkle effacement from 
tretinoin	topical	treatment	results	from	epidermal	hyperplasia,	com-
paction	of	the	stratum	corneum,	thickening	of	the	granular	layer	and	
increased epidermal and dermal glycosaminoglycan deposition.
Tretinoin therapy has also been shown to improve wound 
healing.	Animal	studies	have	also	shown	tretinoin	to	have	an	effect	
on	cytokeratin	16,	which	is	an	important	modulator	of	the	wound	
healing process.11,12	
The	 retinoids	 show	 antiproliferative	 properties,	 promote	
cell	differentiation,	 interfere	with	 the	 tumor	 initiation	process,	 re-
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duce	the	regulation	of	proto-oncogenes,	and	increase	the	expression	
of p53 and pro-apoptotic caspases. It is speculated that they have 
antioxidative effects and thereby decrease the number of sunburn 
cells,	which	are	apoptotic	keratinocytes.	 13-15
However,	to	date,	a	direct	cause-and-effect	relation	has	not	
been established.
Although	 the	 ability	 of	 topical	 tretinoin	 to	 improve	 clini-
cal	features	of	photoaging	is	firmly	established,	the	mechanism	by	
which this occurs needs further study. 
Not	all	of	the	clinical	features	of	photoaging	respond	equal-
ly	to	tretinoin.	Among	them,	hyperpigmentation,	surface	roughness	
and	fine	wrinkles	demonstrate	the	most	consistent	and	significant	
improvement with tretinoin therapy. This positive response to topi-
cal tretinoin is due to improvement or repair in both the epidermal 
(hyperpigmentation	and	surface	roughness)	and	dermal	(fine	wrin-
kles)	components	of	photoaging.	
TRETINOIN AND AGING SKIN
Skin aging is divided into intrinsic or chronological aging 
and extrinsic or photoaging. Extrinsic aging means overlapping en-
vironmental	factors	(mainly	ultraviolet	radiation,	pollution,	smok-
ing,	etc.)	and	lifestyle	(stress)	to	intrinsic	aging,	which	is	enhanced	
through	 the	 following	 mechanisms:	 (i)	 telomere	 shortening;	 (ii)	
generation	 of	 reactive	 oxygen	 species	 (ROS)	 that	damage	 the	mi-
tochondrial	DNA	and	product	matrix	metalloproteinases	 (MMPs)	
that	degrade	 the	dermal	extracellular	matrix;	 (iii)	mutation	of	 the	
p53	tumor	suppressor	gene,	that	is,	making	the	tumor-inducing	and	
promoting the development of preneoplastic and neoplastic lesions 
and	(iv)	reduction	of	growth	hormone	and	sex	steroids.	16-18
The changes are caused in part by cumulative endogenous 
damage	due	to	the	continuous	formation	of	reactive	oxygen	species,	
which are normally generated by mitochondrial metabolism.  19
Despite	 a	 strong	 antioxidant	 defense	 system,	 the	 damage	
generated	 by	 ROS’s	 overproduction	 affects	 cellular	 constituents	
such	as	membranes,	enzymes	and	DNA.	20
Cellular stress accumulated over time potentially impacts 
cell	 metabolism	 and,	 consequently,	 tissue	 regeneration	 and	 func-
tion.	The	progressive	loss	of	function	impairs	tissue	physiology,	as	
it	is	frequently	observed	in	older	skins.	The	diminished	cutaneous	
microvasculature seen in older persons accounts for the progressive 
lower nutritional support in aging skin. 21	In	addition,	obstruction	of	
vessels has been associated with disturbances of the normal archi-
tecture of the vascular plexus in the dermis.  20
In	 intrinsic	 aging,	 morphologic	 changes	 in	 sun-protected	
skin	include	fine	wrinkling	and	laxity;	histology	shows	general	atro-
phy	of	the	extracellular	matrix,	including	reduced	elastin	and	elastic	
fiber	disintegration. 22
On	the	other	hand	in	photoaging,	histopathologic	features	in-
clude	increased	skin	pigment	production,	loss	of	cellular	polarity,	atyp-
ical	epidermal	cells,	skin	thinning	and	atrophy,	mild	inflammatory	in-
filtrate,	degenerative	changes	in	elastic	tissue	(elastosis)	and	decreased	
collagen	tissue	(reduced	synthesis	and	increased	degradation).	22,23
The	 “hallmark”	 of	 the	 histopathology	 of	 photoaging	 is	 a	
change	in	dermal	elastosis,	which	primarily	consists	of	thickened,	
tangled,	and	granular	amorphous	elastic	structures.	These	features	
are	attributed	to	UV-mediated	damage	to	dermal	fibroblasts,	which	
then produce abnormal elastin. 
Actinic	keratosis	(AK)	is	a	pre-neoplastic	skin	disease	main-
ly caused by solar radiation in photoexposed areas. It is character-
ized	by	atypical	proliferation	of	keratinocytes	and	has	a	high	risk	of	
transformation	into	squamous	cell	carcinoma.	
The chronically sun-exposed skin has genomic damage that 
predispose	to	carcinogenesis.	More	than	40%	of	patients	with	a	pre-
vious	diagnosis	of	multiple	AKs	developed	a	non-melanoma	skin	
cancers	(NMSC)	(squamous	cell	carcinoma	or	basal	cell	carcinoma),	
or	a	malignant	melanoma	(MM)	during	a	follow-up	period	of	5	to	
11 years.24
The	appearance	of	AK	configures	the	existence	of	a	field	of	
cancerization	and	early	intervention	can	result	in	primary	preven-
tion of NMSC and MM. 
A	 systematic	 review	 concluded	 that	 topical	 tretinoin	 im-
proves photoaging despite causing irritation; it is considered the 
primary drug for the treatment of aged skin.  25
Other retinoids at proper concentrations and formulated 
in an appropriate delivery vehicle might be useful. Regular use of 
broad-spectrum sunscreens is mandatory. 
CHEMICAL PEELS AND TRETINOIN AS A PEELING AGENT 
Chemical peels not only improve skin appearance but also 
cause histologic changes such as improvement of epidermal atrophy 
and	atypia,	as	well	as	deposition	of	new	subepidermal	collagen.	26,27
Chemical	face	peels	are	generally	classified	according	to	the	
depth	of	penetration	and	its	effect	into:	superficial	(epidermal	gran-
ular	layer	to	the	epidermal	basal	layer),	medium	(papillary	dermis	
to	upper	reticular	dermis),	and	deep	(mid	reticular	dermis).	28,29
Clinical improvement is proportionate to the depth of pene-
tration.	In	superficial	peels	there	is	a	need	for	sequential	application	to	
achieve	the	expected	result.	When	compared	to	other	peels,	the	healing	
process	occurs	faster	and	it	is	considered	safer.	Whereas,	medium	and	
deep peels are performed in a single application with a prolonged peri-
od	for	epithelization,	implicating	in	more	risks	of	infection.
In	2001,	a	case	series	with	15	participants	investigated	clin-
ical	 and	histologic	modifications	 of	 the	 skin	 after	 five	 sessions	 of	
tretinoin peeling. The procedures were performed twice a month 
in	concentrations	of	1-5%.	The	study	showed	good	clinical	and	his-
tologic results applying the peel with 6 to 8 hours in contact to the 
skin	in	patients	with	skin	types	I	to	IV,	with	a	quick	achievement	of	
lightening of melasma in photoaged skin over 2.5 weeks. 30
One	year	later,	these	same	authors	(Cucé	et al.)	recommend-
ed	the	use	of	5%	tretinoin	peel	once	a	week,	in	three	applications.	At	
that	time,	Kligman	commented	this	publication	questioning	stabili-
ty	and	the	advantage	of	such	a	high	concentration.	In	fact,	Kligman	
had	previously	stated	that	applying	a	0.25%	tretinoin	in	a	solution	
of	50%	ethanol	and	50%	polyethylene	glycol	every	night	was	analo-
gous	to	superficial	chemical	peels.	This	approach	was	named	“rapid	
retinization”	of	photoaged	facial	skin.	31,32
In	a	reply	to	Kligman´s	statements,	Cucé	and	Bertino	wrote	
that their intent was to investigte an accurate concentration of treti-
noin	applied	as	a	peeling	agent,	not	as	daily	use,	as	performed	in	
Kligman´s	study. 33
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In	2004,	one	study	demonstrated	 that	1%	tretinoin	peel	was	
probably as effective in the reduction of the pigmentation in melasma 
in	dark-skinned	patients	as	the	standard	peel,	using	70%	glycolic	acid.34
Topical retinoic acid applied daily to the skin produces 
modifications	 in	 the	 epidermis	with	dispersion	of	melanin.35,36 It is 
possible	that	tretinoin	peel,	which	is	classified	as	a	superficial	peel,	
can	induce	the	same	modifications	with	the	advantage	of	being	faster	
and less cumbersome for the treatment of patients with melasma.30,37
In	addition,	1%	tretinoin	peel	provided	the	results	in	a	rela-
tively	shorter	period,	that	is,	12	weeks	as	opposed	to	the	daily	treat-
ment	with	0.1%	tretinoin	cream,	which	required	24	weeks	to	achieve	
the same outcomes.38,39
In	comparison	with	70%	glycolic	acid	peel,	the	1%	tretinoin	
peel	was	less	irritating	and	therefore	better	tolerated.	As	for	effec-
tiveness,	both	treatments	reduced	pigmentation,	with	no	difference	
between the agents.34
Recently,	in	2010,	another	study	was	published	on	the	treat-
ment	of	melasma	by	using	10%	tretinoin	peel.	The	clinical	evalua-
tion found moderate to intense improvement of this condition in all 
patients. This peel was suggested as an alternative modality in the 
treatment	of	melasma,	considering	tolerability	and	efficacy	with	no	
adverse events.40
In	 2011,	 it	 was	 performed	 a	 double-blind,	 randomized	
study	using	5% and	10%	tretinoin	peels	in	30	subjects	aged	between	
25	and	59	years	and	phototypes	III	and	IV.	It	was	concluded	that	the	
treatment	was	 effective	 and	 safe	 for	melasma,	with	 no	difference	
between the concentrations.41
Despite	these	reports	about	the	efficacy	and	safety	of	treti-
noin	peels	 in	high	concentrations,	only	a	few	studies	quantify	the	
concentration of the drug retained in the various layers of the skin 
in vivo. Currently an experimental study assessed in vitro penetra-
tion	of	tretinoin	at	0.25%,	1%	and	5%	concentrations,	in	cream	and	
solution	of	ethanol	and	propylene	glycol	in	equal	parts.	Regarding	
the	viable	epidermis,	there	was	a	greater	retention	of	the	drug	when	
it	was	conveyed	to	5%	solution.42
However there is still a debate about the advantage of high-
ly concentrated tretinoin peel versus its continuous use at low con-
centrations.	A	 study	 from	2015	 showed	 that	most	 of	 the	 tretinoin	
peel was retained in the stratum corneum.44 This might explain why 
tretinoin	peels	do	not	cause	burning,	stinging,	pain	or	irritation	at	
such high concentrations – which is commonly seen in home use of 
commercial formulations of the same agent at low concentrations. 
This	very	superficial	retention	of	tretinoin	peel	implies	that	its	only	
effect	is	an	exfoliation	of	the	stratum	corneum,	without	action	on	the	
RAR	of	viable	keratinocytes	 from	the	deeper	 layers	of	 the	epider-
mis.31,43,44	Therefore	the	sequential	peels	effect	may	not	be	similar	to	
daily use of standard concentrations of tretinoin cream for melasma 
and photoaging. 
Many	reports	attest	efficacy	of	tretinoin	for	repairing	pho-
todamaged	skin,	and	promoting	wound	healing.45-49
A	randomized	and	comparative	study	showed	that,	despite	
being	safe	and	effective,	 the	use	of	 low-dose	oral	 isotretinoin	was	
not	superior	to	topical	0.05%	tretinoin	cream	every	other	night,	for	
the treatment of advanced photoaging.50
For patients with extensive actinic keratosis and diffuse 
photodamage,	peel	is	more	practical	than	current	therapies	for	in-
dividual lesions. 
Given	the	limits	of	tretinoin	peels,	one	should	identify	their	
real	benefits	not	only	in	the	treatment	of	melasma,	but	also	in	photo-
aging,	pre-neoplastic	and	neoplastic	actinic	 lesions	 (field	canceriza-
tion).	Additionally	it	is	essential	to	investigate	the	ideal	concentration,	
vehicle	and	standardization	of	application	(range	and	number)	for	a	
particular	treatment.	For	this	purpose	it	is	necessary	more	controlled,	
randomized	 and	 comparative	 studies	 between	 the	 gold	 standard	
tretinoin cream treatment versus its use as a peeling agent. q
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